IP Library Granted Patent US 7,167,757
Granted Patent B2
US 7,167,757 · App. 10/827,887 · Granted Jan 23, 2007

Energy induced bulking and buttressing of tissue for incontinence

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,167,757
App. No.
10/827,887
Granted
Jan 23, 2007
Kind
B2
Abstract

Devices, systems, and method for treating urinary incontinence generally rely on energy delivered to a patient's own pelvic support tissue to selectively contract or shrink at least a portion of that pelvic support tissue so as to reposition the bladder. Devices and methods apply gentle resistive heating of tissues to cause them to contract without imposing significant injury on the surrounding tissue structures. Alternative heat-applying probes heat tissue structures which comprise or support a patient's urethra. By selectively contracting the support tissues, the bladder neck, sphincter, and other components of the urinary tract responsible for the control of urinary flow can be reconfigured or supported in a manner which reduces urinary leakage.

Claims (19)

1. A method for inhibiting incontinence of a patient, the method comprising:

advancing an electrode of aprobe into a collagenous target tissue, the electrode comprising a needle electrode; and

transmitting energy from an energy-directing element of the probe to the collagenous target tissue, the collagenous target tissue comprising or supporting a urethra of the patient, the energy being transmitted so as to induce a healing response in the collagenous target tissue, the healing response comprising bulking or buttressing of the collagenous target tissue and the bulking or buttressing of the collagenous target tissue inhibiting the incontinence, wherein the energy comprises RF energy delivered with the electrode of the probe.

2. The method of claim 1 , wherein the energy heats the collagenous target tissue sufficiently to induce shrinkage of the collagenous target tissue.

3. The method of claim 1 , further comprising introducing the probe transvaginally.

4. The method of claim 1 , wherein the tissue comprises fascia.

5. A method for inhibiting incontinence of a patient, the method comprising:

introducing a probe into a body of the patient;

penetrating into one or more tissues of the body with a plurality of tips of the probe; and

transmitting energy from the probe into the one or more tissues of the body to heat the tissue so that healing of the tissue results in bulking and buttressing of the tissue, and so that the healing-induced bulking and buttressing of the tissue inhibits incontinence.

6. The method of claim 5 , further comprising inserting the probe into a urethra of the patient.

7. The method of claim 5 , further comprising using a finger inserted into the patient to position the probe.

8. The method of claim 5 , wherein the tissue is heated to a temperature in a range from 60 to 110 C.

9. The method of claim 8 , wherein the energy comprises an electrical potential, and further comprising controlling the temperature of the tissue by limiting the electrical potential and limiting energy applied to the tissue with a timer coupled to the electrical potential.

10. A method for inhibiting incontinence of a patient, the method comprising:

introducing a probe into a body of the patient;

advancing an array of sharpened tips from the probe into a bladder neck and applying an electrical potential to the array;

transmitting energy from the probe into the bladder neck of the patient body to heat the bladder neck so that the bladder neck inhibits incontinence.

11. The method of claim 10 , further comprising using a finger inserted into a vagina of the patient to position the probe.

Assignments (14)
RELEASE OF SECURITY INTEREST Recorded Apr 26, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH HOLDINGS, LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO GENERIC HOLDINGS, INC. (FORMERLY KNOWN AS PAR PHARMACEUTICALS COMPANIES, INC.); ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067240/0001 →
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR PHARMACEUTICAL COMPANIES, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067239/0491 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Sep 17, 2021
From: ASTORA WOMEN'S HEALTH LLC; ENDO PHARMACEUTICALS SOLUTIONS INC.; ENDO PHARMACEUTICALS INC.; PAR PHARMACEUTICAL, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 057538/0978 →
SECURITY INTEREST Recorded Jun 8, 2017
From: ASTORA WOMEN'S HEALTH, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE
Reel/Frame 042743/0278 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME PREVIOUSLY RECORDED AT REEL: 037300 FRAME: 0318. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Sep 6, 2016
From: AMS RESEARCH CORPORATION
To: AMS RESEARCH, LLC
Reel/Frame 039919/0017 →
CHANGE OF NAME Recorded Jan 11, 2016
From: APHRODITE WOMEN'S HEALTH, LLC
To: ASTORA WOMEN'S HEALTH, LLC
Reel/Frame 037473/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2016
From: AMS RESEARCH, LLC
To: APHRODITE WOMEN'S HEALTH, LLC
Reel/Frame 037473/0260 →
CHANGE OF NAME Recorded Dec 15, 2015
From: AMS RESEARCH CORPATION
To: AMS RESEARCH, LLC
Reel/Frame 037300/0318 →
RELEASE OF SECURITY INTEREST Recorded Aug 6, 2015
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: AMERICAN MEDICAL SYSTEMS, LLC; AMS RESEARCH, LLC; LASERSCOPE
Reel/Frame 036285/0146 →
GRANT OF SECURITY INTEREST IN PATENTS Recorded Mar 20, 2014
From: ENDO PHARMACEUTICALS SOLUTIONS, INC.; ENDO PHARMACEUTICALS, INC.; AMS RESEARCH CORPORATION; AMERICAN MEDICAL SYSTEMS, INC.; LASERSCOPE
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 032491/0440 →
RELEASE OF PATENT SECURITY INTEREST Recorded Mar 3, 2014
From: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
To: AMS RESEARCH CORPORATION
Reel/Frame 032380/0053 →
SECURITY AGREEMENT Recorded Jul 22, 2011
From: AMS RESEARCH CORPORATION
To: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
Reel/Frame 026632/0535 →
CORRECTIVE ASSIGNMENT SUPERCEDING ASSIGNMENT RECORDED AT REEL 017770 FRAME 0151 ON JUNE 13, 2005. Recorded Aug 21, 2006
From: SOLARANT MEDICAL, INC.
To: AMS RESEARCH CORPORATION
Reel/Frame 018149/0130 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2006
From: SOLARANT MEDICAL, INC.
To: AMS RESEARCH CORPORATION
Reel/Frame 017770/0151 →